Figure 4 |. Therapeutic vaccination with SNP-IV generates neoAg-specific CD8⁺ T cells with superior anti-tumor capacity.

a, Mice (n = 10) were implanted with MC38, vaccinated with SNP-7/8a (Reps1) and treated with CPI. b,c, Flow analysis of blood stained with tetramer and CD44 antibody (n = 10). d, Tumor growth of SNP-SC or SNP-IV mice (n = 10). e, Average tumor growth and f, survival of Reps1 IV (red), irrelevant IV (maroon), Reps1 SC (blue) and unvaccinated (black) mice. g, Average tumor growth and h, survival of SNP-IV mice treated with isotype (red) or blocking antibodies against CD8⁺ (black), CD4⁺ (blue) and NK cells (purple) (n = 10). i, Average tumor growth and j, survival of mice vaccinated with SNP-IV once (blue), vaccinated once and given CPI (green), vaccinated twice (orange), vaccinated twice and given CPI (red) or untreated (black) (n = 10). k, Flow cytometric analysis of spleens stained with tetramer and CD44 antibody. l, Frequency and m, total number of tetramer⁺ CD8⁺ T cells on day 21 (n = 3). n, Flow cytometric analysis of spleens stained with TCF1 and Granzyme B. Total number of o, stem-like cells (TCF1⁺Granzyme B⁻) and p, effector cells (TCF1⁻ Granzyme B⁺) on day 21 (n = 3) (unpaired t-test). Data are representative of four independent experiments. The bars represent the median (c) or mean (l,m). Mean ± s.e.m. (e,g,i,o,p). Statistics were assessed by two-way ANOVA (e,g,i), Log-rank test (f,h,j), Mann Whitney test (c) and two-tailed unpaired t-test (l,m,o,p).